In vitro activity of the new quinoline derivative ciprofloxacin alone and in combination against various Mycobacterium-, Salmonella- and Escherichia coli strains.
The antibacterial effect of 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-piperazine-1-ylquinoline++ + 3-carboxylic acid (ciprofloxacin, Bay o 9867) has been tested using different test systems and various strains, especially of Escherichia coli, Mycobacterium and Salmonella. Ciprofloxacin shows low MIC's against most of the tested strains. The high in vitro and in vivo activity against Salmonella is most promising for cure of salmonellosis.
D000900:Anti-Bacterial Agents / Q000097:blood / Q000494:pharmacology*; D002851:Chromatography, High Pressure Liquid; D002939:Ciprofloxacin; D004347:Drug Interactions; D004926:Escherichia coli / Q000187:drug effects*; D006801:Humans; D007700:Kinetics; D008826:Microbial Sensitivity Tests; D009161:Mycobacterium / Q000187:drug effects*; D011804:Quinolines / Q000097:blood / Q000494:pharmacology*; D012293:Rifampin / Q000494:pharmacology; D012475:Salmonella / Q000187:drug effects*
D000900:Anti-Bacterial Agents; D011804:Quinolines; D002939:Ciprofloxacin; D012293:Rifampin